Evaluation of Drug Interaction Between HS-10234 and Emtriccitabine

NCT04477096 | Completed Phase 1

• 1 other identifier: HS-10234-108
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

The study is being conducted to evaluate drug interaction between HS-10234 and Emtricitabine after multiple dose in healthy subjects.

Conditions

Healthy Subjects

Keywords

HIV

Outcome Measures

Primary Outcomes (2)

• Pharmacokinetics parameters of HS-10234 and it's metabolite tenofovir, Emtricitabine

  Cmax

  0 - 24 hour on 7th day

• Pharmacokinetics parameters of HS-10234 and it's metabolite tenofovir, Emtricitabine

  AUC0-tau

  0 - 24 hour on 7th day

Secondary Outcomes (7)

• Concentration of HS-10234's metabolite tenofovir-diphosphate in peripheral blood mononuclear cells.

  0 - 24 hour on 7th day

• Incidence of AEs,

  0 - 23 day

• Incidence of AEs,

  0 - 23 day

• Incidence of AEs,

  0 - 23 day

• Incidence of AEs,

  0 - 23 day

Study Arms (1)

single arm for each part: two arms

OTHER

PART1:In the first period, HS-10234 will be administered at 25 mg QD for 7 days. In the second period, HS-10234 at 25 mg in combination with Emtricitabine at 200 mg will be administered QD for 7 days. PART2:In the first period, Emtricitabine will be administered at 200 mg QD for 7 days. In the second period, HS-10234 at 25 mg in combination with Emtricitabine at 200 mg will be administered QD for 7 days.

Drug: HS-10234; Drug: Emtricitabine

Interventions

HS-10234 DRUG

HS-10234

single arm for each part: two arms

Emtricitabine DRUG

Emtricitabine

single arm for each part: two arms

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Voluntarily sign an informed consent before any activities related to this trial and understand the procedures and methods of this trial;
• Aged between 18 and 55 years old (including cutoff value), both male and female;
• Male body weight ≥50.0kg, female body weight ≥45.0kg, body mass index (BMI) is 19\~26 kg/m2 (including both ends);
• Those who signed the informed consent form and had no birth plan within 3 months after the last dose and agreed to take effective contraceptive measures.

You may not qualify if:

• People who have been or are currently suffering from any clinically serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormalities, or any other diseases that can interfere with the test results, Or have a stomach problem or have a history of stomach problems;
• People who have drugs (penicillin or cephalosporin drugs), food, or have a history of allergy to test drugs or similar drugs;
• If the subject have a history of surgery within the 4 weeks prior to the trial or plan to undergo surgery during the study period or have surgery that affected the absorption, distribution, metabolism, and excretion of drugs;
• Those who took any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 14 days before taking the study drug, or those who were within 5 half-lives of the drug at the time of screening; those who plan to take non-study drugs or health products during the trial;
• Those who participated in any drug clinical trial and used any trial drug within 3 months before administration (subject to the informed consent);
• Participate in blood donation within 3 months before administration and the amount of blood donation \>200 mL, or have received blood transfusion;
• Unable or unwilling to follow the lifestyle guidelines required in the plan;
• Smokers or those who smoked more than 5 cigarettes per day in the 3 months before the trial;
• Alcoholics or frequent drinkers within 6 months before the test, that is, drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine) or before administration Alcohol screening positive;
• People who have a history of drug abuse, drug dependence, or a positive drug screen before administration;
• Screening/baseline visit to alanine aminotransferase and/or aspartate aminotransferase and/or alkaline phosphatase and/or total bilirubin exceeds 1.2 times the upper limit of normal;
• Abnormal vital signs (systolic blood pressure \<90 mmHg or \>140 mmHg, diastolic blood pressure \<50 mmHg or \>90 mmHg; pulse \<50 bpm or \>100 bpm) or physical examination, electrocardiogram, laboratory examination, imaging examination, etc. Abnormality has clinical significance (subject to the judgment of the clinical research doctor);
• The QT interval is prolonged during screening (calculated using Bazett's method, male\>450 msec, female\>460 msec);
• Hepatitis B surface antigen, hepatitis C antibody, syphilis serotonin, HIV antibody test positive;
• Women during pregnancy or lactation;

Sponsors & Collaborators

• Jiangsu Hansoh Pharmaceutical Co., Ltd.: lead

Study Sites (1)

Xiangya Hospital, Central South University

Changsha, Hunan, 410013, China

Location

Related Publications (1)

• Luo Y, Chen W, Yang G, Zou C, Huang J, Kuang Y, Shen K, Zhang B, Yang S, Xiang H, Li Z, Pei Q. Study on Pharmacokinetic Interactions Between HS-10234 and Emtricitabine in Healthy Subjects: An Open-Label, Two-Sequence, Self-Controlled Phase I Trial. Infect Dis Ther. 2022 Feb;11(1):175-186. doi: 10.1007/s40121-021-00555-y. Epub 2021 Oct 30.

  PMID: 34727366 DERIVED

MeSH Terms

Interventions

Emtricitabine

Intervention Hierarchy (Ancestors)

Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Deoxyribonucleosides; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides

Study Officials

• Guoping Yang

  Xiangya Hospital of Central South University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 14, 2020
• First Posted: July 20, 2020
• Study Start: August 3, 2020
• Primary Completion: September 24, 2020
• Study Completion: September 24, 2020
• Last Updated: October 1, 2020

Record last verified: 2020-07

Locations

CN (1)